A preliminary evaluation of comparative effectiveness of riluzole in therapeutic regimen for irritable bowel syndrome

Asian Pacific Journal of Tropical Biomedicine

Volumn 4, Issue , 2014, Pages S335-S340

  Mishra, Surya Prakash ^a   Shukla, Sunit Kumar ^b   Pandey, Bajrang Lal ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Glutamate transporter; Irritable bowel syndrome; Riluzole; Visceral pain

Indexed keywords

AMITRIPTYLINE; MEBEVERINE; PROBIOTIC AGENT; RILUZOLE;

ANALGESIA; ARTICLE; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DIARRHEA; DRUG EFFECT; FOLLOW UP; GASTROINTESTINAL SYMPTOM RATING SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MORBIDITY; PAIN ASSESSMENT; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME;

EID: 84914670658     PISSN: 22211691     EISSN: None     Source Type: Journal    
DOI: 10.12980/APJTB.4.2014C205     Document Type: Article

References (25)

1. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Ame 2011; 40(1): 11-19.
2. Fortea J, Prior M. Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden. J Med Econ 2013; 16(3): 329-341.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl 2): II43-II47.
4. Verne GN, Price DD, Callam CS, Zhang B, Peck J, Zhou Q. Viscerosomatic facilitation in a subset of IBS patients, an effect mediated by N-methyl-D-aspartate receptors. J Pain 2012; 13(9): 901-909.
5. Sandkuhler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 2009; 89: 707-758.
6. Roja Rahimi, Shekoufeh Nikfar, Ali Rezaie, Mohammad Abdollahi. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009; 15(13): 1548-1553.
7. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16(5): 547-553.
8. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, Gutiérrez-Udave R, Maldonado-Garza HJ, Bosques-Padilla FJ. Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex 2012; 77(2): 82-90.
9. Diaz Ferrer J, Parra V, Bendaño T, Montes P, Solorzano P. Probiotic supplement (Lactobacillus acidophilus and bulgaricus) utility in the treatment of irritable bowel syndrome. Rev Gastroenterol Peru 2012; 32(4): 387-393. Spanish.
10. Mertz H. Review article: visceral hypersensitivity. Aliment Pharmacol Ther 2003; 17: 623-633.
11. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Taché Y, et al. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006; 130: 1391-1411.
12. Willert RP, Woolf CJ, Hobson AR, Delaney C, Thompson DG, Aziz Q. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-Daspartate receptor. Gastroenterology 2004; 126: 683-692.
13. Gosselin RD, O'Connor RM, Tramullas M, Julio-Pieper M, Dinan TG, Cryan JF. Riluzole normalizes early-life stressinduced visceral hypersensitivity in rats: role of spinal glutamate reuptake mechanisms. Gastroenterology 2010; 138(7): 2418-2425.
14. Kwan AC, Bao T, Chakkaphak S, Chang FY, Ke M, Law NM, et al. Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol 2003; 18(7): 796-802.
15. Jan Svedlund MD, Ingemar Sjödin MD, Gerhard Dotevall MD. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Digest Dis Sci 1988; 33: 129-134.
16. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of hospital anxiety depression scale: an updated review. J Psychosom Res 2002; 52: 69-77.
17. Chan Y, Walmsley RP. Learning and understanding the Kruskal-Wallis one-way analysis-of-variance-by-ranks test for differences among three or more independent groups. Phys Ther 1997; 77(12): 1755-1762.
18. Corder GW, Foreman DI. Nonparametric statistics for nonstatisticians: a step-by-step approach. Hoboken: Wiley; 2009.
19. Robinson DR, Gebhart GF. Inside information-the unique features of visceral sensation. Mol Interv 2008; 8(5): 242-253.
20. Zhou QQ, Verne GN. NMDA receptor and colitis: basic science and clinical implications. Rev Analog 2008; 10(1): 33-34.
21. Hobson AR, Aziz Q. Modulation of visceral nociceptive pathways. Curr Opin Pharmacol 2007; 7(6): 593-597.
22. Rothestien JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transport expression. Nature 2005; 433(7021): 73-77.
23. Sung B, Lim G, Mao J. Altered expression and spinal activity of spinal glutamate transporters after nerve injury contribute to pathogenesis of neuropathic pain in rats. J Neurosci 2003; 23(7): 2899-2910.
24. Heiser V, Engemann S, Bröcker W, Dunkel I, Boeddrich A, Waelter S, et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntingtons's disease by using automated filter retardation assay. Proc Natl Acad Sci USA 2002; 99: 16400-16406.
25. Liu AY, Mathur R, Mei N, Langhammer CG, Babiarz B, Firestein BL. Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)-and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J Biol Chem 2011; 286(4): 2785-2794.